Vitrolife’s Q3 sales beat expectations by 4%, driven by Technologies. Organic growth of 21% in Technologies lifted group sales to SEK884m. The gross margin was supported by a one-off US tariff refund of cSEK9m. Adjusted for the refund, EBITDA of SEK270m was 2% below expectations, as cost inflation weighed on the gross margin.
LÄS MER
